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PART I

GENERAL INTRODUCTION AND OVERVIEW

1

CHAPTER 1
MECHANISMS OF ANGIOGENESIS

The formation of a functional, integral vascular network is a fundamental process
in the growth and maintenance of tissues. Vascularization occurs by three distinct
processes: vasculogenesis, angiogenesis, and arteriogenesis (1).
Cell function and survival is dependent on oxygen and nutrient supply from blood
vessels. During embryogenesis and organogenesis, the coordinated growth of endothelial
cell ensures adequate vessel generation. This process called vasculogenesis, involves the
de novo differentiation of endothelial cells (EC) from mesodermal precursors. The
distinct process of blood vessels generation from pre-existing vessels, called
angiogenesis, is required in adult life during the female reproductive cycle, tissue repair
and wound healing (2). Angiogenesis is the mechanism of blood vessel formation after
the first few days of embryogenesis, and is essential for all tissue growth (3). In adults,
angiogenesis occurs during inflammatory reactions and cancer. The molecular
mechanisms controlling angiogenesis are becoming clearer, and therapy targeting these
processes is becoming closer to clinical trials. The understanding that the formation of
blood vessels depends on the acquisition of a blood supply has led to the development of
new therapies for cancer and other angiogenic diseases based on inhibition of
neovascularization.
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Vasculogenesis
Early in development, vessel formation occurs by a process referred to as
vasculogenesis, in which endothelial cells differentiate and proliferate in situ within a
previously avascular tissue, and then coalesce to form a primitive tubular network (4).
This primary network includes some of the major vessels in the embryo such as the aorta
and major veins. Blood vessels in the embryo form through vasculogenesis; through in
situ differentiation of undifferentiated precursor cells (angioblast) to endothelial cell.

Angiogenesis
Angiogenesis is a complex phenomenon consisting of several distinct processes,
which include endothelial migration and proliferation, extracellular proteolysis,
endothelial differentiation and vascular wall remodeling (2). The term of angiogenesis
was first used to describe the growth of endothelial sprouts from preexisting postcapillary
venules (4). There are at least two different types: true sprouting of capillaries from preexisting vessels, and non-sprouting angiogenesis or intussusception. Sprouting
angiogenesis is the proteolytic degradation of the extracellular matrix is followed by
chemotactic degradation and proliferation of endothelial cells. Almost all known
angiogenesis-activating factors induce one or more of these activities in endothelial cells
in vitro, but it is unclear which factors act in vivo. One may be VEGF, as it is an
endothelial-specific growth and chemotactic factor. Non-sprouting angiogenesis is a
process of splitting pre-existing vessels by transcapillary pillars or posts of extracellular
matrix. Non-sprouting angiogenesis (intussusception) can occur by proliferation of
3

endothelial cells inside a vessel, producing a wide lumen that can be split by
transcapillary pillars, or fusion and splitting of capillaries.

Regulation of angiogenesis

Basement membrane breakdown: proteolytic enzymes

To initiate the formation of new capillaries, endothelial cells of existing blood
vessels must degrade the underlying basement membrane and invade into the stroma of
the neighboring tissue (5). These processes of endothelial cell invasion and migration
require the cooperative activity of the PA system and the MMPs. The PA is serine
protease that converts plasminogen to plasmin. Plasmin has broad substrate specificity
and degrades several ECM components, including fibrin, fibronectin, laminin and the
protein core of proteoglycans ( 5). The MMP family consists of at least 16 members,
which are expressed as latent enzymes with a similar domain structure (6). The activity of
both PAs and MMPs is controlled at least three levels: 1) the expression of uP A, uP AR
and MMPs is upregulated by angiogenic growth factors (7, 8) and cytokines (9). 2) proMMPs and pro-uPA need to be activated proteolytically (10), and 3) the activity of
MMPs, plasmin, and uPA is regulated by TIMPs (11) and PAis (12). PAs and MMPs are
secreted together with their inhibitors, ensuring a stringent control of local proteolytic
activity to preserve normal tissue structure.

Endothelial cell migration and proliferation: angiogenic factors

Endothelial cells start to migrate through the degraded matrix following
proteolytic degradation of the ECM. They are followed by proliferating endothelial cells,
4

which are stimulated by a variety of growth factors, some of which are released from
degraded ECM (13). Angiogenesis can be divided into three classes (14). The first class
consists of the VEGF family, the angiopoietins and ephrins, which specifically act on
endothelial cells. These three different growth factor systems seem to have very different
roles during vascular development. The first characterized vascular-specific growth
factor, VEGF, maintains its position as the most critical driven of vascular formation, as
it is required to initiate the formation of immature vessels by vasculogenesis or
angiogenesis sprouting during development as well as in the adult (15). Angiopoietin 1
(16) and ephrin-B2 (17) are recruited for further remodeling and maturation of this
initially immature vasculogenesis. Following vessel maturation, angiopoietin 1 seems to
continue to be important in maintaining the quiescence and stability of the mature
vasculature. Disruption of this stabilizing signal coincides with reinitiation of vascular
remodeling in the adult. Such destabilization seems to involve the autocrine induction of
a natural antagonist of angiopoietin 1, termed angiopoietin 2 (18). VEGFs, angiopoietins
and ephrin B2 recapitulate their developmental roles during vascular remodeling in the
adult, and administration of individual factors to the adult allows them to reprise these
roles but not to trigger the entire process.
The second class contains most direct acting molecules, including several
cytokines, chemokines (19) and angiogenic enzymes (20) that activate a broad range of
target cells besides endothelial cells. The third group of angiogenic molecules includes
the indirect acting factors, whose effect on angiogenesis results from the release of direct
acting factors from macrophages, endothelial and tumor cells. The most extensively
studied are TNF-a and TGF-~, which inhibit endothelial cell proliferation in vitro. In
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vivo, TGF-B induces angiogenesis and stimulates the expression of TNF-a., FGF-2,
PDGF and VEGF by attracted inflammatory cells (21). TNF-a. has been shown to
increase the expression of VEGF and its receptors, IL-8 and FGF-2 by endothelial cells,
thus explaining its angiogenic properties in vivo (22).

Cell-cell and cell-matrix interaction: adhesion molecules

The processes of cell invasion, migration and proliferation not only depend on
angiogenic enzymes, growth factors and their receptors, but also are mediated by cell
adhesion molecules (23). During invasion and migration, the interaction of the
endothelial cells with ECM is mediated by integrins. lntegrins are a group of cell
adhesion receptors, consisting of non-covalently associated a and

Bsubunits. Endothelial

cells express several distinct integrins, allowing attachment to a wide variety of ECM
proteins (24). Integrin a.vB3 was found to be particularly important during angiogenesis.
In activated endothelium, a.vB3 suppresses the activity of both p53 and the p53 inducible
cell cycle inhibitor, while increasing the bcl2, resulting in an anti-apoptotic effect (25).

6

CHAPTER2
CHEMOKINES AND ANGIOGENESIS

Chemokines are small, cytokine-like, secreted proteins that regulate leukocyte
transport by mediating the adhesion of leukocytes to endothelial cells, the initiation of
transendothelial migration and tissue invasion (26, 27). Four families of chemokines have
been described, based on the relative position of the conserved cystein residues: CC,
CXC, C and CX3C, with the CC and CXC groups being by far the most common ones.
The CXC chemokines are a unique family of cytokines that can regulate angiogenesis in
a disparate manner. CXC chemokines are heparin binding proteins. On a structural level,
they have four conserved cystein amino acid residues, with the first two cysteins
separated by one nonconserved amino acid residues (28, 29). Although the CXC motif
distinguishes this family from other chemokine families, a second domain dictates their
angiogenic activity. The NH2 terminus of the majority of the CXC chemokines contain
the ELR motif, a three amino acid (Glu-Leu-Arg), which procedes the first cystein amino
acid of the primary structure of these cytokines (30). The family members that contain
the ELR motif are potent promoters of angiogenesis (31 ). In contrast, members that are
induced by interferons and lack the ELR motif are potent inhibitors of angiogenesis (32,
33). Thus members of the CXC chemokine family can either promote or inhibit
angiogenesis, and the imbalance of the local expression of these chemokines may be
important in the regulation of angiogenesis
CXC chemokine family members behave as ang10gemc factors including
interleukin-8, growth related genes (GRO-a,~,y), granulocyte chemotactic protein-2
7

(GCP-2) and neutrophil activating protein-2 (NAP-2) (31, 34). ELR+ CXC chemokines
induce endothelial cell chemotactic and proliferative activity in vitro, and angiogenesis in
vivo. Although a specific CXC chemokine receptor that mediates the angiogenic activity
of these cytokines remains to be determined, the candidate CXC chemokine receptors for
this effect are CXCRI and CXCR2. Only IL-8 and GCP-2 specifically bind to CXCRI,
whereas all ELR+ CXC chemokines bind to CXCR2 (35). The ability of ELR+ CXC
chemokine ligands to bind to CXCR2 supports the notion that this represents the receptor
for the mediation of angiogenic activity by ELR+ CXC chemokines. This is supported by
the fact that CXCR2 has the greatest sequence homology with the recently described
human Kaposi's sarcoma herpes virus G protein coupled receptor ( KSHV-GPCR) (36).
IL-8 and GRO-a can act as agonists for KSHV-GPCR, and further augment the signaling
of this receptor (3 7).
Also, the ELR+ CXC chemokines are important mediators of tumorigenesis
related to their angiogenic properties, Studies in melanoma tumors support that all GROs
play a significant role in mediating tumorigenesis related to both their mitogenic and
angiogenic activities (38). The progression of ovarian carcinoma is dependent on
successful angiogenesis, and IL-8 has been determined to play a significant role in
mediating human ovarian carcinoma derived angiogenesis and tumorigenesis. The
expression of IL-8, bFGF, and VEGF was examined in five different human ovarian
carcinoma cell lines (39). The expression of IL-8 was directly correlated with
neovascularization and inversely correlated with survival (39). Thus CXC chemokines
have important implications in promoting angiogenesis.
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The findings of ELR+ CXC chemokines in human tumors provides the unique
opportunity to target a putative receptor for ELR+ CXC chemokine-mediated
angiogenesis. The angiostatic members of the CXC chemokine family include PF4,
monokine induced by IFN-y (MIG), and IFN-y inducible protein 10 (IP-10) (40,41). All
three interferons stimulate the expression of IP-10. MIG is induced only by IFN-y.
Recently, a new ELR- member of the CXC chemokine family, IFN-inducible T cell alpha
chemoattractant (I-TAC), is induced by IFN-y (42). All interferon inducible ELR- CXC
chemokines are potent inhibitors of angiogenesis. This relationship of interferon and
interferon-inducible ELR- CXC chemokines and their biological function are directly
relevant to the function ofIL-18 and IL-12. The ability ofIL-18 and IL-12 to induce IFNy and subsequent interferon-inducible ELR- CXC chemokines explains their ability to
inhibit angiogenesis (43). Thus IL-12 and IL-18 will havea profound effect on the
production ofIP-10, MIG and I-TAC via the induction ofIFN-y.
The subsequent expression of interferon-inducible ELR- CXC chemokines may
represent the final common pathway and explain the mechanism for the attenuation of
angiogenesis related to interferons. Although all three IFN-inducible ELR- CXC
chemokines specifically bind to the CXC chemokine receptor, CXCR3 (44). Potential
mechanisms for the ELR- CXC chemokine, PF4, and its ability to inhibit angiogenesis
that may be relevant to interferon-inducible ELR- CXC chemokines. The ability of PF4
to bind to glycosaminoglycans (GAG: heparin and heparan sulfate) with high affinity
appears to be important to several of its biological functions. PF4 has been shown to
inhibit bFGF and VEGF165 binding to their respective receptors (45, 46). One
mechanism for this effect is related to the generation of PF4-bFGF or PF4-VEGF165
9

heterodimeric complexes, which impairs bFGF or VEGF 165 binding to their respective
receptors. bFGF must undergo dimerization in the presence of endogenous heparin in
order to bind to its receptors. VEGF 165 possesses heparin binding ability similar to
bFGF. PF4 impairs VEGF 165 binding to its receptors on endothelium via a mechanism
similar to what has been reported for its ability to inhibit bFGF. PF4 can inhibit a variety
of endothelial cell mitogens at multiple levels.
These events may be relevant to interferon-inducible ELR- CXC chemokines
because IP-IO has been shown to compete with PF4 for binding and inhibition of
endothelial cell proliferation that may be related to inhibition of the cell cycle. This
supports that interferon-inducible ELR- CXC chemokines may have similar mechanism
for their inhibition of bFGF, VEGF, EGF, and ELR+ CXC chemokine-induced

.
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CHAPTER3
HERPETIC STROMAL KERATITIS: ANGIOGENESIS AND HSK

Infections by herpes simplex virus (HSV) represent an expensive public health
problem. Although only rarely a cause of mortality, HSV infections usually cause painful
and often distressing lesions and are particularly troublesome since symptomatic
recurrent disease is a common outcome once an individual has been infected. Recurrent
lesions on the face and genitalia are the most common expression in some locations such
as the eye and distressing results such as blindness can occur.
One unfortunate sequel to HSV infection is a chronic inflammatory lesion of the
eye called herpetic stromal keratitis (HSK) (47). In humans, this is an important cause of
vision impairment. The murine lesions resemble the human counterpart both clinically
and histopathologically especially in susceptible mouse strains such as BALB/c and A/J
mice infected with the RE strain of HSV -1. HSV -1 ocular infection of susceptible mice
leads to transient mild epithelial lesions caused by virus replication and destruction of
epithelial cells. These lesions quickly heal with little or no scarring and the cornea
appears normal until around day 5-8 post infection. Subsequently, most infected animals
develop progressive corneal opacity, edema, neovascularization, necrosis and ulceration
(48), all of which become evident in a span of 2-3 weeks after infection. Although there
is general agreement that CD4+ T cells are the principal cell types that organize the
inflammatory lesions of HSK, usually viral antigens are not demonstrable during lesion
progression (49). Following ocular infection, virus replication occurs primarily in
epithelial cells and initiates an infiltration of polymorphonuclear (PMN) cells, the
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majority of which are neutrophils, into the underlying corneal stroma. This response
peaks in intensity at 48 hr and then declines by 3-4 days p.i. This pattern of PMN influx
correlates with the time when virus can be detected (50, 51). The neutrophils are involved
in viral clearance and neutrophil response is trivial in response to mutant viruses such as
ICP4-/- and ICP8-/- as well as UV inactivated virus. A second and more aggressive
infiltration of immune cells including neutrophils occurs starting around day 7-8 p.i.
which peaks between 15 and 20 days p.i. (50). This phase of HSK is orchestrated by
CD4+ T cells of the Thl phenotype (52). The notion that CD4+ T cells are the principal
mediators of the lesion came primarily from studies showing that SCID or athymic mice
failed to develop HSK unless reconstituted with CD4+ T cells (53, 54).

Angiogenesis and the pathogenesis of HSK

The pathogenesis of HSK involves the development of new blood vessels in the
normally avascular cornea. Although most studies on HSK have focused on the
participation of different cell types, the cytokines and chemokines induced, and the issue
of which antigens act as targets for CD4+ T cell recognition, the event of new blood
vessel ingrowth into the normally avascularized cornea has been virtually ignored.
Although it remains unclear as to the likely multiple molecules responsible for HSVinduced angiogenesis, the event appears to be a necessary step in HSK pathogenesis.
Recently, Zheng et al. demonstrated that HSV ocular infection acts as a stimulus
for the VEGF family of proteins, potent angiogenesis factors (55). This induction of
VEGF appeared to occur as an indirect consequence of infection and appeared not to
derive from virus infected cells. In fact, using GFP labeled virus and processing cells for
12

VEGF expression by immunohistochemistry, no evidence for double producers was
evident in the infected corneal epithelium. Similarly, the authors have infected peritoneal
macrophage cell line in vitro with HSV, and been unable to detect cells that were both
virus positive and VEGF positive. Thus it remains to be determined how HSV infection
resulted in VEGF expression. Also, angiogenic sprouting during HSK development was
evident at 24hr and increased in magnitude peaking between 15 and 20 days p.i.
Inhibition of VEGF function with the fusion protein mFlt-lgG significantly inhibited both
HSV driven angiogenesis and HSK. However, HSK angiogenesis and severity were not
completely inhibited by anti VEGF likely because the process of HSV induced
angiogenesis is complex with much more than VEGF involved. In addition, treatment of
EMAPII (endothelial monocyte-activating polypeptide II) which is potent antiangiogenesis cytokine resulted in diminished HSK severity (56). The effect of EMAPII
was at least in part directed at the function of VEGF. EMAPII inhibited VEGF induced
angiogenesis in micropocket assay. Also, EMAPII appears to function by causing
apoptosis in corneal epithelial cells. Recently, mouse bioactive CpG containing
oligodeoxynucleotides (ODN), but not control ODN, caused angiogenesis (57). This
effect was significantly inhibitable by anti-VEGF antibody. Furthermore, HSV DNA
itself could similarly cause angiogenesis with the effect also inhibitable by anti-VEGF
antibody. Thus HSV DNA released from dying cells could be one mechanism of
angiogenesis factor induction.
A novel observation was that angiogenesis represents a crucial event in HSK
pathogenesis and that neovascularization provides a logical target for the therapeutic
management of HSK. The process of new capillary formation from preexisting vessels,
13

angiogenesis, is a complex physiological event which is strictly controlled, occurring
only very rarely under normal conditions. In contrast, there are number of serious disease,
among them solid tumor growth, rheumatoid arthritis and several eye disease, which is
characterized by unrestricted new capillary growth and which are described as angiogenic
disease (58). As it currently stands, the research on angiogenesis should add to our
knowledge about this topic and could lead to the ultimate development of new therapies
for the control of HSK.
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CHAPTER4
SPECIFIC AIMS AND RA TI ON ALE
Infection of the eye with HSV may result in blinding immunoinflammatory lesion
in the cornea called herpetic stromal keratitis (HSK). Studies in mouse models have
shown that HSK is a multistep process that primarily is the consequence of an immunoinflammatory reaction orchestrated by CD4+ T cells. Although most studies on HSK
have focused on the participation of different cell types, the cytokines and chemokines
induced, and the issue of which antigens act as targets for CD4+ T cell recognition, the
event of new blood vessel ingrowth into the normally avascularized cornea has been
virtually ignored. Although it remains unclear as to the likely multiple molecules
responsible for HSY-induced angiogenesis, the event appears to be a necessary step in
HSK pathogenesis. As it currently stands, it remains unclear how HSV infection results

.

.

.

m ang1ogenes1s.
The specific aims are

1. To define how herpes simplex virus (HSV) infection of the cornea results in
initial neovascularization of the cornea.
2. To determine the cellular and molecular mechanisms in HSV induced
angiogenesis during herpetic stromal keratitis (HSK) pathogenesis.
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PART II

IL-12 SUPPRESSES THE EXPRESSION OF OCULAR
IMMUNOINFLAMMATORY LESIONS BY EFFECTS ON
ANGIOGENESIS
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CHAPTER!
ABSTRACT
Topical application of plasmid DNA encoding IL-12 to the cornea of mice prior
to ocular infection with herpes simplex virus type 1 (HSV) results in diminished corneal
immunoinflammatory lesions. Such herpetic stromal keratitis (HSK) reactions in humans
represent an important cause of blindness. The effect of IL-12 pretreatment acted via
inhibitory effects on corneal neovascularization, rather than by inhibiting viral replication
or the function of CD4+ T cells that mediate HSK. The anti-angiogenesis induced by IL12 DNA application was mediated indirectly via the cytokine IFN-y and one or both of
two chemokine molecules, IP-10 and MIG. Thus IL-12 DNA administration lacked
modulatory effects on HSK in GKO mice, indicating the necessary involvement of IFN-y
induction for antiangiogenesis. In contrast, exposure of GKO mice to IP-10 DNA did
suppress the severity of HSK. Furthermore, treatment with specific antisera to IP- IO and
MIG in HSV infected mice abrogated the IL-12 induced an inhibitory effect on lesion
severity. Taken together, these data indicate that the HSV induced ocular immunoinflammatory lesions can be modulated by IL-12 and that this effect results from
chemokine inhibition of angiogenesis. The use of antiangiogenesis therapy might
represent a useful control measure against HSK.
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CHAPTER2
INTRODUCTION
Herpes simplex virus (HSV) infection of the eye can result in a blinding
immunoinflammatory lesion in the corneal stroma ( 1). In humans this is an important
cause of vision impairment. The lesion, as studied in animal model systems, occurs as a
consequence of a CD4+ T cell orchestrated immunopathological reaction, but the nature
of target antigens which drive T cell activation remain ill-defined (1, 2). In humans,
herpetic stromal keratitis (HSK) is controlled with anti-inflammatory drugs and severe
cases may require corneal transplantation. It is anticipated that a full understanding of
HSK pathogenesis may lead to novel therapies to control this distressing lesion.
Evidence to data implicates CD4+T cells of the type 1 phenotype as the mediator
of HSK (3, 4). Moreover pretreatment with type 2 cytokines can suppress HSK severity
(5, 6). In addition, treatment with the cytokine IL-10, before the full clinical phase
develops, can result in lesion suppression or even resolution (5). HSV infection itself
results in the production of a notable IL-12 cytokine response (7), which presumably
helps set the stage for the type 1 T cell mediated CD4+ inflammatory reaction. We
anticipated that if animals were exposed to IL-12 prior to infection this would further
potentiate type 1 CD4+ T cell responses and result in more severe HSK lesions.
Unexpectedly, however, ocular exposure to plasmid DNA encoding IL-12 resulted in
diminished rather than exacerbated stromal lesions. Conceivably, the lesion modulating
effects ofIL-12 could be explained by the induction of antiviral cytokines such as IFN-y,
or the induction of cellular defenses such as NK cells known to exert protective effects
against HSV infection (8). In addition, IL-12 has been reported to express
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immunosuppressive effects on CD4+ T cell priming by inducing IFN-y and iNOS
activation that in turn causes T cell apoptosis (9). Furthermore IL-12 may inhibit tumor
seemingly by mediated an antiangiogenesis effect (10).
As we have documented elsewhere, angiogenic sprouting into the normally
avascular cornea appears to be an essential event in the pathogenesis of HSK (11, 12).
This process appears as a necessary prelude to invasion by the CD4+ T cells which drive
the inflammatory reaction (11). The present report adds support to the notion that IL-12 is
antiangiogenic and that the inhibitory effect of IL-12 on HSK lesion severity proceeds by
an effect on angiogenesis rather than by antiviral or suppressive effects in T cell function.
As observed with some tumor systems, the antiangiogenic effect of IL-12 appeared to act
indirectly by inducing IFN-y which in turn caused the expression of two antiangiogenic
factors interferon inducible protein 10 (IP- I 0) and monokine induced by interferon
gamma (MIG) (13). Accordingly, our results demonstrate that administration of IL-I2
DNA to normal, but not IFN-y -/- mice, caused upregulation of two cytokines IP-IO and
MIG in the cornea. These inhibited HSV induced angiogenesis and consequently the
severity of HSK. Our results are discussed in terms of novel approaches that merit testing
to control HSK lesions.
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CHAPTER3
MATERIALS AND METHODS
Mice

Female 4- to 5- week old BALB/c and C57BL/6 mice were purchased from
Harlan Sprague-Dawley (Indianapolis, Ind.). Female 4- to 5- week old iNOS KO mice
and female 6- to 8- week old GKO mice purchased from The Jackson Laboratory
(BarHarbor, ME). GKO mice contain a nonfunctional IFN-y gene and are on a BALB/c
background. BALB/c and C57BL/6 mice were housed conventionally, and KO mice were
housed in sterile microisolator cages in the animal facility. All manipulations were
performed in a laminar flow hood. To prevent bacterial infection, all mice received
treatment with sulfamethoxazole/trimethoprim (Biocraft, Elmond Park, NY) at the rate of
5ml/200ml of drinking water. All investigations followed guidelines of the Committee on
the Care of Laboratory Animals Resources, Commission of Life Sciences, National
Research Council. The animal facilities of the University of Tennessee are fully
accredited by the American Association of Laboratory Animal Care.

Virus

HSV-1 strain RE (kindly provided by Dr. Robert Lausch, University of Alabama,
Mobile, AL) was used in all procedures. Virus was grown in Vero cell monolayers
(A TCC cat.no.CCL81 ), titrated, and stored in aliquots at -80°C until used.
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Plasmid DNA preparation
Plasmid DNA encoding murine IL-12 was kindly provided by Dr. Kenji Okuda
(Yokohama City University School of Medicine, Yokohama, Japan). Plasmid DNA
encoding murine IP-10 was constructed by PCR amplification of the full coding region.
All plasmid DNAs used in this work were inserted into the pCDNA3 expression vector
(Invitrogen, Inc., San Diego, Calif). The plasmid DNAs were purified by polyethylene
glycol precipitation by the method of Sambrook et al. (14) with some modifications. The
quality of DNA was measured by electrophoresis on 1 % agarose gel. The protein
expression of the different plasmids was determined by RT-PCR and dot blot after in
vitro transfection into Chinese Hamster Ovary (CHO) cells.

Corneal HSV infection
Corneal infections of all mouse groups were conducted under deep anesthesia
induced by the inhalant anesthetic methoxyfurane (Methofane; Pittman Moore,
Mondelein). The mice were lightly scarified on their corneas with a 27 gauge needle, and
a 2.5µ1 drop containing lxl06 PFU ofHSV-1 RE for BALB/c, lxl07 PFU ofHSV-1 RE
for C57BL/6 and iNOS KO mice, and lx10 4 PFU of HSV-1 RE for GKO mice was
applied to the eye and gently massaged with the eyelids.

Clinical observations
The eyes were examined on different days after infection for the development of
clinical lesions by slit-lamp biomicroscopy (Kawa Co, Nagoya, Japan), and the clinical
severity of keratitis of individually scored mice was recorded. The scoring system was as
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follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer;
+5, corneal rupture and necrotizing stromal keratitis. The severity of angiogenesis was
recorded as previously described (12). According to this system, a grade of 4 for a given
quadrant of the circle represents a centripetal growth of 1.5mm toward the corneal center.
The score of the 4 quadrant of the eye were then summed to derive the NV index (range
0-16) for each eye at a given time point (12).

Virus recovery and titration

Swabs of the corneal surface were collected at various time points post infection.
The swabs were put into sterile tubes containing 500µ1 of DMEM with 10 IU of
penicillin/ml and 100µg of streptomycin (Life Technologies, Grand Island, NY)/ml and
stored at - 80°C. For detection and quantification of virus in the swabs, the samples were
thawed and vortexed. Individual subsamples (200µ of each sample) were further diluted,
and viral titers were determined by a plaque assay performed on Vero cells as described
elsewhere (15).

Plasmid DNA administration

100µg of plasmid DNA was suspended in 4µ1 of sterile PBS. Corneas were
scarified using a 27 gauge needle in a criss-cross pattern and the plasmid was
intraocularly administered on 6 and 3 days before virus infection.
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HSV-specific lymphoproliferation

This assay has been described in detail elsewhere (16). Briefly, at day 15
following HSV ocular infection, the splenocytes of vector, IL-10 or IL-12 DNA treated
mice were enriched for T cells by a nylon wool column and used as responder
populations. These T cells were restimulated in vitro with irradiated syngeneic enriched
nai've dendritic cell (DC) or DC infected with UV-inactivated HSV (MOI of 1.5 before
UV inactivation) and incubated for 5 days at 37°C. Con A (5µg/ml) was used as a
polyclonal positive control and incubated for 3 days. Eighteen hours before harvesting,
[ 3H]

thymidine was added to the cultures.

Cytokine assay

For cytokine (IFN-y) assay, splenocytes from mice were suspended in 10% RPMI
1640, and 106 cells in 1 ml were stimulated in vitro with irradiated syngeneic enriched
DC pulsed with UV-inactivated HSV (MOI, 5.0. before UV inactivation). Similar
number of cells were Con A stimulated (5µg/10 6 cells/ml) in 96 well plates. Plates were
incubated at 37°C for 72h. The supernatant fluid was collected and stored at -80°C until
use. These supernatants were screened for the presence of IFN-y by ELISA as described
previously (16).

Isolation of RNA

At day 3 post infection, corneas were carefully dissected, freed of scleral tissues,
minced and homogenized in TRI Reagent (Molecular Research Center, Cincinnati, OH).
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Total RNA was isolated by manufacturer's protocol. All the procedures including RTPCR were performed in a laminar flow hood.

RT-PCR

Total cellular RNA (l0µg/ml) was reversed transcribed using oligo (dT) primers
and reverse transcriptase (Promega) according to protocols described previously (17).
The cDNA was made by the reverse transcription reaction incubated at 42°C for 90 min.
The cDNA (2µ1) was subjected to 35 cycles of amplification as described (5) using
primers. The primers used follows: B-actin-1, 5'-GTGGGGCGCCCCAGGCACCA-3';
B-actin-2,

5 '-CTCCTT AA TGTCACGCACGAT-3';

IFN-y- 1,

5'-

ATGAACGCTACACACTGCAT C-3'; IFN-y-2, 5'-GCAGCGACTCCTTTTCCGCTT3';

IP-10-1,

5'-ACCATGAACCCA

AGTGCTGCCGTC-3';

GCTTCACTCCAGTT AAGGAGCCCT-3 ';

IP-10-2,

MIG- I,

5'-

5' -

ACTCAGCTCTGCCA TGAACTCCGC-3'; MIG-2, 5 '-AAAGGCTGCTCTGCCAG
GGAAGGC-3'; IL-10-1, 5'-ATGAAATATACAAGTTATATC-3'; IL-10-2, 5'-TTAGC
TTTTCA TTTTGA TCA T-3'. The PCR products were separated by agarose gel
electrophoresis.

Preparation and administration of Abs

Rabbit polyclonal Abs to IP-10 and MIG were produced by Biosynthesis
(Lewisville, TX) using synthetic peptides selected from the IP-10 and MIG protein
sequences (CIHIDDGPVRMRAIGK and CISTSRGTIHYKSLKDLKQF APS) coupled to
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carrier protein KLH. Mice were given intraperitoneally 250µ1 of antibodies to IP-I 0
and/or MIG I day before infection and 3 day after infection.

Corneal micropocket assay

In vivo angiogenic activity was assayed in the avascular cornea of BALB/c mouse
eyes, as previously described (18). Briefly, mice were pretreated with plasmid DNA
encoding IP-IO twice intraocularly before implantation. Pellets for insertion into the
cornea were made by combining rhVEGF-I65 (40µg, R&D system), sulcralfate (IOmg,
Bulch Meditec) and hydron polymer in ethanol (I20mg/Iml ethanol, Interferon
Sciences), and applying the mixture to a I5xI5mm2 piece of synthetic mesh (Tetko). The
mixture was allowed to air dry and fibers of the mesh were pulled apart, yielding pellets
containing 90ng of VEGF. Pellets containing rhVEGF were implanted into an
intracorneal pocket (Imm from the limbus) afterwhich the eyes were evaluated for
corneal neovascularization. The extent of the neovessel ingrowth was recorded by direct
measurement using calipers (Symbol of Quality, biomedical research instruments,
Rockville, Maryland) under stereomicroscopy. The number of vessels originating from
the limbus was counted over the entire orbit, and the area of angiogenesis was calculated
according to the formula for an ellipse.
A=[(clock hours)x0.4x(vessel length in mm)xn]/2. Each clock hours is equal to 30° at
the circumstance.

Statistical analysis

Significant differences between groups were evaluated using the Student's t test.
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CHAPTER4
RESULTS
IL-12 DNA decreases the severity and incidence of HSK

Since murine HSK appears to be an inflammatory lesion orchestrated mainly by
type 1 cytokine producing CD4+ T cells ( 1, 2), expression of IL-12 on the cornea prior to
infection was expected to enhance the severity ofHSK. In fact, however, as shown in Fig
1, the opposite outcome was observed. In such experiments, susceptible BALB/c mice
were exposed to 100µg of IL-12 DNA on the ocular surface 6 and 3 days before virus
infection. In each experiment, animals received either IL-12 DNA or vector DNA and
then 106 PFU of HSV-1 RE on their scarified corneas. As is clearly evident (Fig. 1), the
majority of animals given IL-12 DNA showed lesions of diminished severity and
incidence in comparison to vector DNA treated individuals. By day 10, the IL-12 DNA
treated mice had significantly reduced clinical lesions and corneal opacity {p<0.05)
compared to vector treated controls. These differences continued at days 12 (P<0.05), 15
(P<0.05) and 20 (P<0.01). In the IL-12 DNA treated eyes, approximately 80-90% of eyes
showed controlled or resolved lesions during a 21 day observation period. In vector DNA
treated eyes, resolution was evident in a maximum of 10% of eyes. These results indicate
that IL-12 DNA possesses an inhibitory effect on the expression of HSK lesions.
However, IL-12 given after HSV infection had no significant effect on lesion severity
(data not shown).
Three possibilities were considered to explain the inhibitory effect of IL-12.
Firstly, IL-12 exposure would likely result in IFN-y expression in the cornea which in
turn could be antiviral. As documented in a later section, exposure of the cornea to IL-12
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DNA did result in IFN-y mRNA expression. However, measurement of the duration and
concentration of virus in ocular washing at various times after infection in IL-12 and
vector-treated mice revealed no significant differences (Fig. 2). A second explanation for
the inhibitory effect of IL-12 DNA was that IL-12 could exert immunosuppressive effects
on CD4+ T cell priming as reported in some other systems (9). As shown in Fig. 3,
evidence for any such immunosuppression was not obtained. Accordingly, measurement
of HSV specific proliferative (mainly a function of CD4+ T cell function) (P=0.3) and
cytokine production of splenocytes at 15 day post infection (P=0.4) revealed no evidence
of immunosuppression. In contrast pretreatment with IL-IO DNA did result in diminished
HSV specific proliferative responses.
Antiangiogenic effects were the third possibilities to explain by IL-12 DNA
inhibition of HSK. The data recorded in Fig. 4, support this mechanism. In these
experiments, the extent of angiogenic sprouting from the limbus into the normally
avascular cornea was recorded at various times following HSV infection in IL- 12 DNA
and vector DNA treated mice. As is evident, the extent of angiogenesis was significantly
reduced on day 5 and at subsequent examination periods in animals that received IL-12
DNA pre-exposure. As is also shown, expression of IP-IO DNA also caused reduced
angiogenesis (described later).

IL-12 inhibition of HSK acts via IFN-y induction

In several systems where IL-12 exerts functional effects, it does so by inducing
intermediary cytokines such as IFN-y (19,20). Other activities such an
immunosuppression may be the consequence of iNOS induction (9, 21, 22). To test the
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role of both IFN-y and iNOS activity during the IL-12 induced inhibition of HSK, the
effects of IL-12 pretreatment was compared in ocularly infected normal and knockout
mice. Fig. SC records the inhibitory effects of IL-12 DNA pretreatment in BALB/c and
IFN-y -/- mice. Whereas IL-12 pretreatment inhibited the severity of HSK in BALB/c
mice, the effect was not evident in GKO mice (P=0.7). In the latter mice, animals were
infected with 102 less virus than given to BALB/c mice, since GKO mice die of
encephalitis if infected with the virus doses used to produce HSK in BALB/c mice [23].
To measure the influence of iNOS expression, C57BL/6 (B6) mice and B6 background
iNOS -/- mice were used. Both groups of mice were IL-12 or vector DNA treated prior to
HSV infection and the severity of HSK lesions compared. Fig. SA and SB show IL-12
DNA pretreatment resulted in diminished HSK lesion severity in both B6 and iNOS -/mice, with the IL-12 inhibitory effect ofIL-12 even more apparent in the iNOS -/- mice.
These data indicate that the antiinflammatory effect of IL-12 likely dose not proceed via
nitric oxide production as has been reported to occur in some other systems (9, 22).

Possible mechanism by which IL-12 mediates antiangiogenesis

In some tumor systems IL-12 was observed to mediate antiangiogenesis, acting
indirectly on intermediary steps such as IFN-y production that in tum induced IP-10 and
MIG antiangiogenic factors (13, 24). The modulating effect of IL-12 DNA pretreatment
on HSK and corneal angiogenesis would also seem to involve a similar mechanism. Thus
as shown in Fig 6, topical administration of IL-12 DNA led to increased expression of
mRNA for IFN-y as well as for both IP-10 and MIG. There was no upregulation ofIL-10
mRNA, another possible mediator of HSK suppression as shown in previous work (5, 6).
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The upregulation of IP-10 and MIG mRNA appeared to be the consequence of IFN-y
expression since measurement of IP-10 and MIG mRNA in IL-12 DNA treated GKO
corneas revealed no detectable IP-10 and MIG mRNA expression.
In another experiment, the effects on HSK lesion severity was measured in mice
pretreated with either IP-10, IL-12 or vector DNA prior to infection with HSV. As is
readily apparent (Fig. 7A), BALB/c mice pretreated with IP-10 DNA had reduced HSK
lesion severity and incidence almost to the same degree, as did those animals pretreated
with IL-12 DNA. Furthermore, IP-10 DNA pretreated animals also showed reduced
angiogenesis scores in comparison to vector DNA exposed animals (Fig. 4). Interestingly,
IL-12 DNA pretreatment had no effect on HSK expression in GKO mice, preexposure of
such mice to IP-10 DNA did result in significantly reduced HSK lesion severity and
incidence (Fig. 7B). Taken together the above data support the idea that IL-12 reduces
HSK expression via effects on angiogenesis mediated indirectly by IFN-y induced IP-10
and MIG expression.

IP -10 and MIG mediate antiangiogenesis in the HSK model

To further evaluate the role of IP-10 and MIG in antiangiogenesis mediated by
IL-12 DNA two further sets of experiments were performed. In the first, mice were
pretreated with IL-12 DNA, infected with HSV and then either given control lg or
polyclonal rabbit anti IP-10 or/and anti MIG antisera. These sera were shown to mediate
appropriate specific effects in previous studies (25, 26, 27). The results show that
treatment with either anti IP-10 (P<0.05) or anti MIG (P<0.02) partially reversed the IL12 inhibitory effect on HSK. When both antisera were combined, the IL-12 DNA
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inhibitory effect was abrogated (Fig. 8). In separate experiments, the effect of IP-10 DNA
was tested for antiangiogenesis in a corneal micropocket assay using the potent
angiogenesis factor VEGF to induce angiogenesis. As is recorded in Fig. 9, IP-10 DNA
resulted in 58 % inhibition of VEGF induced angiogenesis.
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CHAPTERS
DISCUSSION

This report demonstrates that the application of plasmid DNA encoding IL-12 to
the cornea of mice prior to ocular infection with HSV results in diminished
immunoinflammatory lesions. Such herpetic stromal keratitis (HSK) reactions represent
an important cause of human blindness (1). The effect of IL-12 pretreatment acted via
inhibitory effects on corneal neovascularization, rather than by inhibiting viral replication
or the function of CD4+ T cells that mediate HSK. The antiangiogenesis induced by IL12 DNA application was mediated indirectly via the cytokine IFN-y and one or both of
two chemokine molecules IP-10 and MIG. Thus IL-12 DNA administration had no
modulatory effect on HSK in GKO mice, indicating the necessary involvement ofIFN-y
induction. In contrast, exposure of GKO mice to IP-10 DNA did suppress the severity of
HSK. Furthermore, suppression with specific antisera of IP-10 and MIG expression in
HSV infected mice abrogated the IL-12 induced inhibitory effect on HSK. Taken
together, our results indicate that the ocular immunoinflammatory lesion that results from
HSV infection can be modulated by IL-12 and that this effect results from chemokine
inhibition of angiogenesis.

As first shown by our group (5), and confirmed by others (28), the surface
application of plasmids encoding various proteins is a convenient means of expressing
molecules in the cornea. By such an approach, we showed that pre-exposure to Th2
chemokines such as IL-4 and IL-10 reduced HSK lesions caused by HSV infection. Such
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lesions are immunoinflammatory with CD4+ T cells producing type I cytokines such as
IFN-y and IL-2, the principal mediators of the inflammation (4). During lesion resolution
Th2 cytokines may predominate (5). Initial experiments with IL-12 DNA administered to
the eye were done in an attempt to exacerbate lesions and to facilitate disease induced by
nonvirulent mutant viruses. Surprisingly, however, lesions were diminished rather than
exaggerated. Since IL-12 induces IFN-y, as shown to occur in the cornea in the present
report, a logical explanation for the modulatory effect on HSK lesion severity was the
antiviral activity of IFN-y. Indeed, clearance of HSV infection from peripheral sites often
appears to be a correlate of IFN-y production (29, 30). In line with this observation,
animals unable to produce IFN-y (GKO mice), are markedly more susceptible to HSV
infection (23). Nevertheless, such mice can still express HSK, as long as they are infected
with lower, non-lethal doses of virus (23). In our model, although IL- 12 DNA resulted in
IFN-y expression, this appeared inadequate to curtail viral replication. Thus, in IL-12
DNA treated mice, levels and duration of viral expression were almost identical to those
in control vector DNA treated animals.

The HSK lesions are mediated principally by CD4+ T cells although the identity
of antigens which drive these cells have yet to be identified. Conceivably the inhibitory
effects of IL-12 administration might result from immunosuppressive effects of IL-12 on
CD4+ T cell priming. In fact, such a mechanism was advocated to explain the inhibitory
effects of IL-12 on CD4+ T cell mediated uveitis (9). In this instance, suppression was
mediated by upregulation of iNOS which led to NO production. The latter interfered with
Bel 2 regulated apoptosis in developing CD4+ effector cells (9). Such a mechanism
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appeared not to be the explanation for our observations. Thus the HSV specific CD4+ T
cell responses appeared normal in IL-12 treated mice. In addition, the inhibitory effect of
IL- 12 on HSK expression was unimpaired in mice unable to express iNOS because of
gene knockout. Indeed, in such mice the inhibitory effects of IL-12 were even more
marked but we have no explanation for this observation.

The hypothesis favored to explain the inhibitory effect of IL-12 on HSK lesions
was an effect on corneal neovascularization. Accordingly, ocular HSV infection results in
angiogenic sprouting into the normally avascular cornea (12). A molecular explanation
for such events is lacking but the VEGF family of potent angiogenesis factor appears as
involved (12). Angiogenesis appears necessary during HSV pathogenesis to permit
appropriate access of CD4+ T cells and some other inflammatory components to the
corneal stroma ( 11 ). In support of such ideas, we have shown elsewhere that inhibition of
angiogenesis with a cytokine that causes vascular endothelial cell apoptosis results in
diminished HSK lesions (12). The present report further demonstrates the relationship of
angiogenesis and HSK lesion expression. Thus we show that IL-12 pretreatment results
in diminished angiogenesis which correlated with reduced HSK lesions. The effect of IL12 appeared as indirect with IL-12 serving to upregulate IFN-y which in turn caused
expression of two CXC chemokines IP-10 and MIG. These latter molecules are the actual
angiogenesis inhibitors. At least for IP- I 0, we demonstrated, using a corneal micropocket
assay, that it could inhibit the angiogenesis effect of VEGF, a factor involved in HSV
angiogenesis ( 12). Others have also shown the inhibitory effect of IP-IO against
angiogenesis caused by fibroblast growth factor (31 ). Moreover, it was apparent that
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inhibition with specific antisera of either IP- IO or MIG (but preferably both
simultaneously) reversed an IL-I2 induced effect on angiogenesis and HSK expression.
That IFN-y was an essential component of the antiangiogenesis, was supported by
observations that the IL-I2 induced effect did not occur in GKO mice. Taken together
our data support the mechanism advocated to explain the antitumor effect of IL- I 2
observed in some systems. Namely that IL-I2 induces IFN-y which then upregulates
antiangiogenic chemokines (13, 25, 32).

The molecular mechanism by which IP-IO and MIG inhibit angiogenesis has yet
to be established. To this end, studies in the cornea may represent a more convenient and
accessible model than those in solid tumors or in vitro systems. Evidence supports the
fact that at least two types of receptors can be involved in responses to IP-IO and MIG
(33, 34, 35). These are heparan sulfate proteoglycans (HSPG) as well as CXCR3.
Curiously, CXCR3 can be expressed on effector T lymphocytes and engagement of the
receptor by IP-IO or MIG can result in chemotaxis. Such an event could recruit
inflammatory T cells to the cornea, and conceivably serve to increase the severity of
HSK. However, since neovascularization may be necessary to permit invasion by CD4+ T
cells, the effect on angiogenesis, likely mediated by HSPG receptor engagement (35) will
be dominant. Future therapy of HSK could benefit from targeting angiogenesis receptors
such as HSPG. Such issues merit further investigation.
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APPENDIX

Figure. 1. BALB/c mice are protected from HSK by IL-12 DNA administration.

Groups of animals (n=7) were treated intraocularly at 3 and 6 days before virus
infection with I00µg of either IL-12 DNA{_) or vector DNA(_). 3 Day after second
treatment, animals were infected with 106 PFU of HSV-1 RE on their scarified corneas
and subsequently scored for lesion severity by slit lamp biomicroscopy. The data are
complied from seven independent experiments.
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Figure. 2. Persistence of virus following HSV-1 RE infection.

BALB/c mice were treated with IL-12 DNA(_} or vector DNA(_) and then
infected with 106 PFU (n=8) of HSV-1 RE on their scarified corneas. Eye swabs were
collected every day post infection, and the virus titer was determined by the agarose
overlay method. The virus titer was calculated as log PFU per milliliter. Data represent an
average of 8 numbers of mice per group. *P= 0.5 at day 4 post infection. (P value
represents that there is no significant difference between vector and IL-12 DNA treated
group.
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Figure. 3. HSY-specific Th-cell proliferative responses (A) and IFN-y production (B)
of HSV stimulated splenocytes.

Groups of animals (n=7) were treated intraocularly at 3 and 6 days before virus
infection with 100µg of either IL-12 DNA (_) or vector DNA (_). 3 Day after second
treatment, animals were infected with 106 PFU of HSV -1 RE on their scarified corneas.
Mice were sacrificed 15 days following HSV -1 ocular infection. Stimulation indices were
calculated by cpm of HSV infected cells/cpm of uninfected cells. For the measurement of
IFN-y, the T cells were restimulated in vitro with irradiated DC infected with UVinactivated HSV-1 KOS. Seventy-two hours later, culture supernatants were collected
and analyzed for IFN-y by ELISA. Significant differences (P<0.01) between IL-10 DNA
and vector DNA treated mice are indicated by an asterisk (Stimulation Index), and a
double asterisk (IFN-y production).
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Figure. 4. Administration of IL-12 DNA or IP-10 DNA inhibits angiogenesis.

Groups of animals (n=7) were treated twice with 100µg of either IL-12 (_), IP-10
(_) or vector DNA{_) intraocularly 6 and 3 days before virus infection and were infected
with 106 PFU of HSV-1 RE on their scarified corneas 3 day after second treatment of
DNAs. The animals were then examined for the extent of angiogenesis as described in
Materials and Methods. The data are complied from three independent experiments. *
P<0.05 between IL-12 DNA or IP-10 DNA and vector DNA at days 5, 7, 10, 14 and 18
post infection.
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Figure. 5. IL-12 DNA treatment fails to protect GKO mice (B) from HSK, but not
iNOS KO mice (A).

Groups of BALB/c, C57BL/6, and iNOS KO mice (n=7) were infected with 106
PFU and GKO mice (n=7) were infected with 104 PFU of HSV-1 RE on their scarified
corneas. These mice were given l00µg of each of IL-12 DNA(_} and vector DNA(_}
intraocularly 3 and 6 day before virus infection. The mice were examined clinically by
slit lamp biomicroscopy, and the severity of lesions was scored on a 0-to-5 scale as
described in Materials and Methods. Data are complied from three independent
experiments. Significant reductions of HSK severity and incidence in IL-12 DNA treated
C57BL/6 and iNOS KO mice are indicated by an asterisk (P<0.05).
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Figure. 6. Expression of transcripts for IFN-y, IP-10 and MIG in corneas of BALB/c
orGKO mice.
Groups of BALB/c mice (n=7) or GKO mice(n=7) received lO0µg ofIL-12 DNA
or vector DNA and infected with 106 PFU (10 4 PFU for GKO mice) of HSV-1 RE on
their scarified corneas. At 3 day post infection, corneas were isolated from mice and
treated with Trizol reagent. Total RNAs were extracted from the corneas as described in
Materials and Methods. The RNA samples were subjected to RT-PCR analysis. Similar
results were obtained in two separate experiments. Lane 1: cornea from na"ive BALB/c
mice, Lane 2: cornea from vector DNA treated BALB/c mice, Lane 3: cornea from IL-12
DNA treated BALB/c mice, Lane 4: cornea from vector DNA treated GKO mice, Lane 5:
cornea from IL-12 DNA treated GKO mice.
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Figure. 7. Inhibitory effect of IP-10 DNA on lesion severity of HSK in BALB/c (A)
and GKO (B) mice. (IP-10 DNA decreased the incidence as well as lesion severity in
both BALB/c and GKO mice-incidence data not shown.)
Groups of mice (n=7) were treated intraocularly with IP-10 DNA (_) or vector DNA (_)
3 and 6 day before virus infection and infected with 106 PFU ( 104 PFU for G KO mice) of
HSV-1 RE on their scarified corneas. The mice were examined clinically by slit lamp
microscopy, and the severity of lesions was scored on a 0-to-5 scale as described in
Materials and Methods. Data are complied from three independent experiments.
Significant reductions of HSK severity in IP-10 DNA treated BALB/c and GKO mice are
indicated by an asterisk (P<0.05).
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Figure. 8. Antibodies to IP-10 and MIG inhibit IL-12 DNA mediated protective
effect on HSK.
Groups of mice (n=7) were treated intraocularly with IL-12 DNA or vector DNA
3 and 6 day before virus infection. These mice were injected intraperitoneally with
control lg (- ), anti-IP-IO (- ), anti-MIG (~) or anti-IP-IO plus anti-MIG

(◊)

I day before

virus infection and 5 day after virus infection. Groups of mice received I 06 PFU of HSVI RE on their scarified corneas. The mice were examined clinically by slit lamp
biomicroscopy, and the severity of lesions was scored on a O-to-5 scale. Data are
complied from two independent experiments. A significant reduction of the effect of ILI 2 DNA in anti IP-10 plus anti-MIG treated mice is indicated by an asterisk (P<O.OI).
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Figure. 9. Pretreatment of IP-10 DNA inhibits recombinant VEGF induced
angiogenesis.
Groups of mice (n=7) were treated intraocularly with IP-10 DNA or vector DNA,
and hydrogen pellets containing rhVEGF (90ng) were implanted into the corneal pockets.
The total number of neovessels originating in the limbus and the area of
neovascularization were calculated. A significant reduction of angiogenesis in IP-10
DNA treated mice is indicated by an asterisk (P<0.01).
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PART III

MATRIX METALLOPROTEINASE-9 PLAYS A MAJOR ROLE IN
ANGIOGENESIS CAUSED BY OCULAR INFECTION WITH
HERPES SIMPLEX VIRUS

66

This part is a lightly revised version of a paper by the same name published in the

Journal of Clinical Investigation in 2002 by Sujin Lee, Mei Zheng, Bumseok Kim, and
Barry T. Rouse:

Lee, S., M. Zheng, B. Kim, and B. T. Rouse. Matrix metalloproteinase-9 plays a major
role in angiogenesis caused by ocular infection with herpes simplex virus. Journal of

Clinical Investigation. 2002. In press.
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CHAPTER 1
ABSTRACT

In this report, we demonstrate that HSV infection of the cornea results in the upregulation of the matrix degrading metalloproteinase enzyme MMP-9. This enzyme was
shown to contribute to the neovascularization process that occurs in the corneal stroma in
response to HSV infection. The likely source of MMP-9, at least initially after infection,
was neutrophils that were signaled to invade the cornea soon after infection. Corneal
infiltrating neutrophils were shown to express MMP-9 and preventing the neutrophil
response with specific mAb diminished MMP-9 expression as well as the extent of
angiogenesis.

Further supporting a role for MMP-9 in HSV induced corneal

angiogenesis was the observation that inhibition of MMP-9 with the specific inhibitor
TIMP-1 resulted in reduced angiogenesis. In addition, angiogenesis was diminished in
ocularly infected MMP-9 -/- mice. Our results demonstrate that MMP-9 is involved in
angiogenesis caused by HSV. Since angiogenesis appears to represent a vital step in the
pathogenesis of herpetic stromal keratitis these results indicate that targeting MMP-9 for
inhibition should prove useful for the therapy of HSK.
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CHAPTER2
INTRODUCTION

One of the more distressing lesions caused by herpes simplex virus (HSV)
infection is vision impairment and blindness resulting from a chronic
immunoinflammatory reaction in the corneal stromal. Studies on experimental herpetic
stromal keratitis (HSK) in animal models have revealed that the pathogenesis involves
numerous cellular and molecular participants. One early essential event appears to be
neovascularization of the normally avascular corneal stroma. This event is assumed to be
necessary to assist corneal access of some of the cellular orchestrators of HSK (1). In
line with this notion, inhibition of new blood vessel development serves to moderate the
severity of HSK lesions(2, 17). Currently, the mechanisms by which HSV infection
results in corneal angiogenesis remain ill-defined, and more than likely involves multiple
participants could be involved. These include the VEGF family of proteins, potent
angiogenesis factors under both physiological and pathological circumstances and known
to be produced following ocular infection with HSV (2). The VEGF proteins, as well as
certain chemokines, induce angiogenesis by binding to receptors on vascular endothelial
cells causing them to undergo growth and movement.

Other molecules influence

angiogenesis by breaking down the extracellular matrix so facilitating neovessel growth.
Matrix degrading proteases include the collagenases (eg, matrix metalloproteinase 2 and
9) and heparanases (3). Several MMP proteins appear involved in tumor angiogenesis,
but the role of such molecules in viral induced angiogenesis has not been described.
In the present report, we have evaluated if MMP-9 is involved in angiogenesis
following infection of the mouse eye with HSV-1. Our results demonstrate that MMP-9,
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whilst undetectable in normal eyes, is produced in the cornea in response to HSV
infection. A prominent cell type that produces MMP early after infection was invading
neutrophils. When MMP-9 levels were suppressed, as could be achieved by neutrophil
depletion, by inhibition with the specific inhibitor TIMP-1, or by using mice strains
unable because of gene knockout to produce MMP-9, HSV induced angiogenesis was
inhibited. In addition, the results further demonstrate that inhibition of angiogenesis is
reflected in the reduced severity of subsequent HSK lesions. Our observations are
discussed in terms of the value of controlling angiogenesis in the therapy of herpetic eye
disease.
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CHAPTER3
MATERIALS AND METHODS
Mice

Female 4- to 5- week old BALB/c mice were purchased from Harlan SpragueDawley (Indianapolis, Ind). Female 4 week old 129 Sv/Ev mice were purchased from
Taconic Farms (Germantown, NY). MMP-9 KIO mice were kindly provided by Drs
Robert M. Senior and J.Michael Shipley (Washington University School of Medicine,
St.Louis, MO). BALB/c and 129 Sv/Ev mice were housed conventionally, and KIO mice
were housed in sterile microisolator cages in the animal facility. To prevent bacterial
infection, all mice received treatement with sulfamethoxazole/trimethoprim (Biocraft,
Elmond Park, NY) at the rate of 5ml/200ml of drinking water. All investigations
followed guidelines of the committee on the Care of Laboratory Animals Resources,
Commission of Life Sciences, National Research Council. The animal facilities of the
University of Tennessee are fully accredited by the American Association of Laboratory
Animal Care.

Virus

HSV-1 strain RE (kindly provided by Dr.Robert Lausch, University of Alabama,
Mobile, AL), HSV-1 KOS 1.1 (kind gift of Dr.David Knipe, Harvard Medical School,
Boston, MA) and the mutant virus n12 (ICP4-/-) (gift from Dr.David Knipe) were used.
Viruses were grown in Vero cell monolayers (ATCC cat.no. CCL81 ), titrated, and stored
in aliquots at -80YC until used. UV inactivation of the wild type virus was carried out for
5 minutes.
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Corneal HSV infection

Corneal infections of all mouse groups were conducted under deep anesthesia
induced by the inhalant anesthetic methoxyfurane (Methofane; Pittman Moore,
Mondelein). The mice were lightly scarified on their corneas with a 27 gauge needle, and
a 2.5µ1 drop containing 1H106 PFU of HSV-1 RE for mice was applied to the eye and
gently massaged with the eyelids.

Plasmid DNA preparation

Plasmid DNA encoding murine TIMP-1 was kindly provided by Dr.Dylan
Edwards (University of East Anglia School of Biological Sciences, Norwich, England).
TIMP-1 DNA was inserted into the pCDNA3 expression vector (lnvitrogen, Inc., San
Diego, CA). The pCDNA3 was used as a negative control against TIMP-1 DNA. The
plasmid DNAs were purified by polyethylene glycol precipitation by the method of
Sambrook et al. (4) with some modifications. The quality of DNA was measured by
electrophoresis on 1% agarose gel. The protein expression of TIMP-1 DNA was
determined by RT-PCR and dot blot after in vitro transfection into Chinese Hamster
Ovary (CHO) cells.

Plasmid DNA administration

100µg of plasmid DNA was suspended in 4µ1 of sterile PBS. Corneas were
scarified using a 27 gauge needle in a criss-cross pattern and the plasmid was
administered on 3 and 6 days before virus infection.
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Clinical observations

The eyes were examined on different days after infection for the development of
clinical lesions by slit-lamp biomicroscopy (Kawa Co, Nagoya, Japan), and the clinical
severity of keratitis of individually scored mice was recorded. The scoring system was as
follows: 0, normal cornea; + 1, mild corneal haze; +2, moderate corneal opacity or
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer;
+5, corneal rupture and nectotizing stromal keratitis. The severity of angiogenesis was
recorded as previously described (5). According to this system, a grade of 4 for a given
quadrant of the circle represents a centripetal growth of 1.5 mm toward the corneal
center. The score of the 4 quadrant of the eye were then summed to derive the NV index
(range 0-16) for each eye at a given time point (5).

Gelatin Zymography

Zymographic assays for gelatinase were performed as described previously (6). In
brief, protein extracts (20µg) of corneas from mice were subjected to SDS-P AGE on
gelatin-containing acrylamide gels (8% acrylamide and 1% gelatin) under nonreducing
conditions. After electrophoresis, gels were washed three times with 2.5% Triton X-100
for 3 hrs to remove SDS. Gels were then rinsed briefly with water followed by incubation
overnight at 3TfC in reaction buffer containing 50mM Tris, pH7.5, 0.15M NaCl, l0mM
CaCh and 0.05% (w/v) Sodium azide. The gels were stained with 0.5% (w/v) Commassie
Brilliant Blue R-250. Gelatinolytic activity was detected as a transparant band against a
dark blue background.
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Depletion of neutrophils with mAb
Clone RB6-BC5 was kindly provided by Dr. E.Balish (University of Wisconsin
Medical School, Madison, WI) with permission of Dr. R.L. Coffman (PharMingen, San
Diego, CA). The cells were grown in RPMI 1640 with 10% FBS. Hybridoma cells were
injected i.p. (5H10 6 cells/mouse) into BALB/c nude mouse. Ascitic fluid was collected,
centrifuged at 400H g for l 5min, pooled, and stored at -20YC until ready for use.
Delipidized ascitic fluid containing rat lgG2b Abs against HLA-DRS (clone SFR3-DR5;
ATCC, Rockville, MD) was used as isotype control. The ascitic fluids were titrated for
the Ab content using an indirect ELISA as described previously (7). BALB/c mice were
administered S00µg of anti Gr-I Ab i.p. on day -3 and+ 1 with HSV-1 RE on the cornea.
Control mice were treated similarly with rat anti-HLA DRS Ab.

Immunohistochemistry
Eyes were removed and snap frozen in OCT compound (Miles, Elkhart, IN). Sixmicron-thick (6µm) sections were cut, air dried and fixed in cold acetone for IOmin. The
sections were then blocked with 3% BSA and stained with anti-mMMP-9 (Santa Cruz
Biotech) for 3hrs, which was followed with biotinylated anti-goat lg (Santa Cruz,
Biotech) for 1hr. Frozen sections were also stained with biotinylated anti-Gr-I
(Pharmingen) for 3 hrs. The sections were then treated with horseradish peroxidaseconjugated streptavidin (1:1,000, Jackson Immunoresearch Laboratories, Inc) and 3,3'diaminobenzidine substrate (Biogenex, San Ramon, CA) and then counterstained with
hematoxylin.
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Corneal micropocket assay

In vivo angiogenic activity was assayed in the avascular cornea of BALB/c mouse
eyes, as previously described (8). Briefly, mice were pretreated with plasmid DNA
encoding TIMP-1 twice intraocularly before implantation. Pellets for insertion into the
cornea were made by combining rhVEGF (40µg, R&D system), sulcralfate ( 10mg, Bulch
Meditec) and hydron polymer in ethanol (120mg/1ml ethanol, Interferon Sciences), and
applying the mixture to a 15H 15mm2 piece of synthetic mesh (Tekto ). The mixture was
allowed to air dry and fibers of the mesh were pulled apart, yielding pellets containing
90ng of VEGF. Pellets containing rhVEGF were implanted into an intracomeal pocket
(1mm from the limbus). Then the eyes were evaluated for corneal neovascularization.
The extent of the neovessel ingrowth was recorded by direct measurement using calipers
(Symbol of Quality, biomedical research instruments, Rockville, Maryland) under
stereomicroscopy. The number of vessels originating from the limbus was counted over
the entire orbit, and the area of angiogenesis was calculated according to the formula for
an ellipse.
A=[(clock hours)H 0.4H (vessel length in mm)H n]/2
Each clock hours is equal to 30 at the circumstance.

Statistical analysis

Significant differences between groups were evaluated using the Student's t test.

75

CHAPTER4
RESULTS
HSV Infection Results in MMP-9 Expression

Corneas were taken at various time points after ocular infection with HSV -1 and
analyzed by zymography for the presence of the collagen degrading enzymes MMP-2 and
MMP-9. Two bands of activity were evident. A band identified as MMP-2 was present
in normal corneal extracts. Moreover its levels appeared not to vary at different times
after virus infection (Fig 1). A second band, identified as MMP-9 was not present in
normal tissue but was present at varying amounts in extracts from virus infected animals.
A peak of activity appeared at 48 hr p.i. followed by a decline then subsequently a second
rise of activity starting around day 7. The secondary peak corresponded with the
developing clinically evident HSK (Fig. 1).

The primary peak of MMP-9 activity was suspected to derive from neutrophils
which were previously to be prominent stromal invaders at around 2 days post infection
(9,10). Evidence that such invading neutrophils were a source of MMP-9 was obtained
by different lines of experimentation. Firstly, histological sections of corneas at 2 days
post infection revealed prominent inflammatory cell infiltrates (Fig. 2A). The majority of
invading cells were neutrophils most of which could be shown by immunocytochemistry
to possess intracellular MMP-9 (Fig.2B). Cells positive for MMP-9 were not found in
the virus infected epithelium nor was it evident in any cells in sections from uninfected
animals.

A second approach incriminating neutrophils as the source of MMP-9

demonstrated that diminished MMP-9 levels were present in corneal extracts of animals
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that were virus infected but depleted of neutrophils by treatment with specific antineutrophil mAb (Fig. 3).

Finally, infection of eyes with UV inactivated virus or replication defective HSV
mutants, which induce negligible neutrophil responses, also failed to cause detectable
levels of MMP-9 production (Fig 4). Taken together, these experiments support a role
for corneal stroma invading neutrophils as a principal source of MMP-9 production early
after ocular HSV infection.

MMP-9 Knockout Mice Show Diminished Angiogenesis and Reduced Severity of
HSK
Mice lacking MMP-9 express10n because of gene knockout have reduced
angiogenesis in several tumor systems (11,12). As shown in Fig. 5, a similar outcome
was evident in mice ocularly infected with HSV -1. Thus in a comparison of the extent of
ocular angiogenesis in MMP-9 -/- mice compared to 125 Sv/Ev control animals, levels
were around 50% less in the MMP-9 -/- animals when measured over a 20 day test
period.

These differences were shown to be statistically significant (P<0.01).

Furthermore, when animals were followed to measure the severity HSK on days 12 and
21 p.i., the severity was significantly less in the MMP-9 -/- animals.

In an additional experiment, ocularly infected MMP-9 -/- animals were analyzed
to determine if a stromal neutrophil response was evident in such animals. As shown in
Fig. 2C,a prominent response was indeed present at 48 hr p.i. Once again these data
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support the notion that invading neutrophils are in normal animals a principal source of
MMP-9.

Effect of MMP-9 inhibitor on HSV induced angiogenesis

The metalloproteinase MMP-9 is known to be inhibited by TIMP-1, with this
molecule serving to minimize the duration of MMP-9 activity in some tumor
angiogenesis systems (13). To measure the effect of TIMP-1 on HSV-1 induced MMP-9
induction, animals were given either plasmid DNA encoding TIMP-1 or control plasmid
DNA vector on the cornea. Animals were treated at 3 and 6 days prior to HSV-1
infection, after which the extent of angiogenesis was compared in TIMP-1 and vector
DNA treated animals. Preliminary experiments in uninfected mice revealed that TIMP-1
DNA treatment led to TIMP-1 mRNA expression in corneal extracts (data not shown).
The results in Fig. 6 indicate that the extent of angiogenesis in TIMP-1 plasmid DNA
treated animals was significantly decreased compared to vector treated animals during the
3-5 day observation period. As a further measure of the effect of TIMP-1 inhibition on
MMP-9, corneal extracts were taken at 48 hr from TIMP-1 and vector DNA treated
animals for measurement of MMP-9 levels by zymography. The results shown in Figure
7 demonstrate significantly diminished MMP-9 signals in samples from TIMP-1 treated
animals. These experiments provide further evidence for a role of MMP-9 in HSV
induced angiogenesis.

TIMP-1 DNA Inhibits VEGF Induced Angiogenesis by its Effect on MMP9 Activity

In a previous report, we demonstrated that ocular infection with HSV induces the
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potent angiogenesis factor VEGF family of proteins with these playing an important role
in corneal angiogenesis (2). Since TIMP-1 is not expected to inhibit VEGF, and these
molecules are present following HSV infection, observing the inhibitory effects of TIMPDNA on HSV angiogenesis was perhaps surprising. Hence experiments were done using
a corneal micropocket assay to measure the effect of pretreatment of eyes with TIMP-1
DNA on the angiogenic response to VEGF. The results shown in Figure 8, indicate that
such pretreatment diminished by about 50% neovascularization caused by VEGF. To
determine if levels of MMP-9 might account for such differences corneal extracts from
mice with VEGF containing and control micropockets were tested by zymography for
MMP-9. Unlike normal corneas VEGF implanted eyes do produce MMP-9. Moreover in
TIMP-1 DNA pretreated VEGF implanted eyes MMP-9 levels were markedly diminished
compared to VEGF implanted vector treated eyes (Fig 9). These results demonstrate that
MMP-9 represents a significant component of HSV induced angiogenesis being also
involved indirectly in angiogenesis caused by other known angiogenesis factors.
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CHAPTERS
DISCUSSION

In this report, we demonstrate that HSV infection of the cornea results in the upregulation of the matrix degrading metalloproteinase enzyme MMP-9. This enzyme was
shown to contribute to the neovascularization process that occurs in the corneal stroma in
response to HSV infection. The likely source of MMP-9, at least initially after infection,
was neutrophils that are signaled to invade the cornea soon after infection. Corneal
infiltrating neutrophils were shown to express MMP-9 and preventing the neutrophil
response with specific mAb diminished MMP-9 expression as well as the extent of
angiogenesis.

Further supporting a role for MMP-9 in HSV induced corneal

angiogenesis was the observation that inhibition of MMP-9 with the specific inhibitor
TIMP-1 resulted in reduced angiogenesis. In addition, angiogenesis was diminished in
ocularly infected MMP-9 -/- mice. Our results demonstrate that MMP-9 is involved in
angiogenesis caused by HSV. Since angiogenesis appears to represent a vital step in the
pathogenesis of herpetic stromal keratitis (14) these results indicate that targeting MMP-9
for inhibition should prove useful for the therapy of HSK.

Neovascularization of the cornea is a prominent event following HSV infection of
the mouse eye. Growth of new blood vessels from the limbus are evident as early as 24
hr p.i. with vessels in some instances growing to the central cornea by 14 days p.i. (15).
By this time, lesions of HSK have become evident.

Characteristically, the virus

replicates for only a few days in corneal epithelial cells, but angiogenesis and stromal
immunoinflammatory reaction progress in severity for 2-3 weeks ( 16, 17).
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Since

inhibiting angiogenesis, at least if begun early, diminished the severity of HSK, we have
suggested that neovascularization of the cornea is a necessary step in the pathogenesis of
HSK (17). It likely serves to provide access to the cornea of T lymphocytes that
orchestrate the immunoinflammatory lesions of HSK. A crucial unsolved problem is to
explain how a relatively brief period ofHSV replication in the corneal epithelium leads to
the rapid angiogenic sprouting from vessels at the corneal limbus which ultimately may
involve almost the whole cornea. We anticipate that the infection signals the production
of many molecules involved both in angiogenesis and inflammation. This report is the
first to document a potential role of MMP-9 in HSV induced angiogenesis. However,
MMP-9 is well known as involved in several tumor angiogenesis systems (18,19,20) and
has also been shown to participate in ocular wound healing (21,22).

The role of MMP-9 is assumed to play in angiogenesis is to facilitate the growth
of new blood vessels by breaking down the extracellular matrix (23). Numerous groups
of molecules participate in angiogenesis by inducing growth of vascular endothelial cells
(24,25). In the HSV model, previous results have shown that the VEGF family of
proteins are involved (2). In addition, certain chemokines such as MIP-2, are known to
be produced during HSV-1 ocular infection (26), are also expected to contribute to
angiogenesis. Consequently, abrogating angiogenesis where so many different types of
molecules are seemingly involved, could prove to be problematic.

MMP-9, however, represents a logical target for therapy, since this component
acts as the principal degrader of the ECM, at least in certain tumor angiogenesis systems
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(27 ,28).

Moreover ECM degradation appears to represent an essential step in

angiogenesis (29), facilitating the growth of angiokine stimulated vascular components.
Consequently the function of MMP-9 is expected to amplify the effect of other
angiogenesis factors. Indeed, in our studies, we demonstrated that inhibiting MMP-9, as
could be done with the specific inhibitor TIMP-1, also served to inhibit angiogenesis
mediated by VEGF. Such results could mean that the combined use of reagents that
inhibit MMP-9 along with specific inhibitors of certain angiogenesis factors may achieve
more compete control of ocular angiogenesis. We are currently testing such notions in
our HSV angiogenesis model.

Early after HSV infection, the cellular course of MMP-9 was shown to be the
neutrophils that promptly invade the corneal stroma following HSV infection of the
overlying epithelium. Preventing this, neutrophil response both diminished detectable
levels of MMP-9 and reduced the extent of angiogenesis. However, it is not clear if
neutrophils remain as the only source of MMP-9 nor in fact if the function of MMP-9 is
necessary after the initial stages of HSV induced angiogenesis. It could well be that only
a certain degree of corneal neovascularization is actually required to permit invasion by
inflammatory T cells and other cell types involved in lesions of HSK. In line with this,
our preliminary investigations have indicated that there is no benefit in terms of the
progress of HSK, of inhibiting neovascularization after the initial stage. Ultimately to
fully control HSK lesions could require approaches that reverse established angiogenesis.
This issue is under investigation in our laboratory.
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APPENDIX

Figure 1. MMP-9 is present in cornea during HSK, and MMP-9 activities are highly
correlated with HSK legion severity.

Groups of animals were infected with 106 PFU of HSV -1 RE on their scarified
corneas. The mice were examined clinically by slit lamp microscope, and the severity of
lesion was scored on a Oto 5 scale (A). At day 2 post infection, animals were sacrificed,
corneas excised and pooled from 6 eyes, and homogenized. The concentrations of protein
were measured by Bradford method. Corneal extract samples (20µg/lane) were analyzed
by gelatin zymography. Numbers above gel represent days post infection. High MMP-9
activities were measured at day 2, 15, 18 and 20 post infection. The data are complied
from three independent experiments.
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Figure 2. MMP-9 and neutrophil infiltration into corneas of BALB/c and MMP-9
KO mice.
BALB/c and MMP-9 KO mice were infected with 106 PFU HSV-1 RE on their
scarified corneas. At day 2 p.i. mice were sacrificed, and the eyes were snap-frozen in
OCT compound. (A) Histopathology of infiltrating cells in the cornea of BALB/c. (left;
narve, right; day 2 p.i). (B) Immunohistochemistry for MMP-9. (left; narve, right; day 2
p.i). (C) Immunohistochemistry for Gr-I (left; BALB/c, right; MMP-9 KO)
(magnification, X200)
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Figure 3. Neutrophil depeletion markedly diminishes MMP-9 production.

Groups of mice received intraperitoneally with anti-Gr- I Ab twice as described in
Materials and Methods, and groups of mice received an irrelevant control isotype
matched rat Ab. Groups of mice were infected on the scarified cornea with 106 PFU of
HSV-1 RE. At day 2 post infection, animals were sacrified, corneas excised and pooled
from 6 eyes, and homogenized. Corneal extract samples (20µg/lane) were analyzed by
gelatin zymography (A). Lane 1 : HSV-1 infected corneas after PMN depletion, Lane 2 :
HSV-1 infected corneas after injection of isotype control lg.
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Figure 4. Replication defective HSV mutants fail to produce MMP-9.

BALB/c mice were infected on the cornea with 106 PFU of the specified virus
after scarifying the cornea with a 27 gauge needle. At day 2 post infection, animals were
sacrificed, corneas excised and pooled from 6 eyes, and homogenized. The
concentrations of protein were measured by Bradford method. Corneal extract samples
(20µg/lane) were analyzed by gelatin zymography. Similar results were obtained in three
independent experiments. Lane 1 : 106 PFU of UV inactivated HSV-1 RE, Lane 2 : 106
PFU ofICP4 -/-, Lane 3: 106 PFU ofHSV-1 KOS, Lane 4: 106 PFU ofHSV-1 RE, Lane
5 : trauma control, Lane 6 : na'ive.
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Figure 5. MMP-9 knock out mice are protected from HSK pathogenesis.

Groups of 129 Sv/Ev wild type (4 wk old) and MMP-9 KIO mice (4 wk old) were
infected with 106 PFU of HSV -1 RE on their scarified corneas. The mice were examined
clinically by slit lamp microscope, and the severity of lesions was scored on a 0 to 5
scale. The mean clinical scores at day 5, 10, 15 and 19 are ploted for all groups. Also, the
animals were examined for the extent of angiogenesis as described in Materials and
Methods. * P<0.05 between WT and KIO mice at day 5 (angiogenic scoring) and at day
10 (HSK lesion severity).
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Figure 6. TIMP-1 DNA inhibits angiogenic scoring and HSK lesion severity.

Groups of animals were treated twice with 100µg of TIMP-1 DNA and vector
DNA intraocularly 6 and 3 day before virus infection and were infected with 106 PFU of
HSV-1 RE on their scarified corneas 3 day after second treatment of DNAs. The mice
were examined clinically by slit lamp microscope, and the severity of lesions and the
extent of angiogenesis were scored as described in Materials and Methods. Data are
complied from three independent experiments. Significant differences (P<0.05) between
TIMP-1 DNA and vector DNA treated mice indicated by an asterisk (angiogenic
scoring), and a double asterisk (severity).
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Figure 7. TIMP-1 DNA inhibits MMP-9 activity at day 2 post infection.

Groups of animals were treated twice with 100µg of TIMP-1, vector and ~-gal
DNA intraoculary 6 and 3 day before virus infection and were infected with 106 PFU of
HSV -1 RE on their scarified corneas 3 day after second treatment of DNAs. At day 2
post infection, animals were sacrified, corneas excised and pooled from 6 eyes, and
homogenized. Corneal extract samples (20µg/lane) were analyzed by gelatin
zymography. Lane 1 : human zymography standard. Lane 2 : corneas treated with vector
DNA. Lane 3 : corneas treated with ~-gal DNA. Lane 4 : corneas treated with TIMP-1
DNA.
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Figure 8. Pretreatment of TIMP-1 DNA inhibits recombinant VEGF induced
angiogenesis.
Groups of mice were treated intraocularly with TIMP-1 DNA or vector DNA, and
hydrogen pellets containing rhVEGF (90ng) were implanted into the corneal pockets. The
total number of neovessels originating in the limbus and the area of neovascularization
were calculated.
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Figure 9. TIMP-1 DNA reduces VEGF induced angiogenesis by inhibition of MMP9 activity.
Groups of mice were treated intraocularly with TIMP-1 DNA or vector DNA, and
hydrogen pellets containing rh VEGF (90ng) were implanted into the corneal pellets. At
day 4 post treatment, animals were sacrificed corneas were excised and pooled from 8
eyes, and homogenized. The concentrations of protein were measured by Bradford
method. Corneal extract samples (20 µg/lane) were analyzed by gelatin zymography.
Similar results were obtained in three independent experiments. Lane 1 : corneal sample
from TIMP-1 DNA treated group. Lane 2 : corneal sample from vector DNA treated
group.
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PARTIV
CONCLUSION
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This study was aimed to determine the role of angiogenesis and to modulate HSV
induced angiogenesis in HSK pathogenesis. The results from this study indicate that
angiogenesis is an essential step in HSK pathogenesis.
In the first part of this study, the efficacy of plasmid DNA encoding IL-12
administered prophy lactically was investigated for their modulating effects on lesion and
angiogenesis caused by HSV-1 ocular infection. Thus, plasmid DNA encoding IL-12 was
applied to the ocular surface, since it was supposed this might help push the HSV specific immune response to subsequent ocular infection more towards the pathogenic
Thi pattern. Unexpectedly, however, the results demonstrated that ocular treatment by
IL-12 DNA led to suppression of HSV-1 induced angiogenesis and lesion severity in
HSK pathogenesis. Lesions were diminished in IL-12 DNA pretreated animals, and 8090% of animal controlled or even resolved lesions compared to 10% in controls. The
inhibitory effect of IL-12 on angiogenesis is mediated by intermediate proteins IFN-y and
two CXC chemokines, such as IP-10 and MIG.
In the second part of this dissertation, the role of MMP-9, a stromal matrix
degrading enzyme, was investigated. This study shows that the MMP-9 was upregulated
following virus infection of the cornea. Two peaks were evident. One, at 48 hr post
infection, correlated with the initial neutrophil response. In fact, such cells were shown to
produce MMP-9, with neutrophil suppression inhibiting MMP-9 levels in corneal
extracts. The MMP-9 appeared to be associated with angiogenesis since its inhibition
with the specific inhibitor TIMP-1 led to significant inhibition of angiogenesis. Similarly
MMP-9 KO mice had diminished angiogenesis and HSK in comparison to control mice.
Therefore, based on the studies presented here, it can be concluded that
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angiogenesis is necessary in HSK pathogenesis. Although it remains unclear as to the
likely multiple molecules responsible for HSY-induced angiogenesis, from the above
experiments we found one major molecule, MMP-9. Furthermore, antiangiogenic
molecules such as IL-12, IP-10 and TIMP-1 ameliorated HSK lesion severity and
incidence.
In conclusion, we hope that these studies should add to our knowledge about
angiogenesis in HSV-1 ocular infection and could lead to the development of new
therapies for the control of lesion severity in HSK pathogenesis.
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